Literature DB >> 28031419

Serum Levels of Apolipoproteins and Incident Type 2 Diabetes: A Prospective Cohort Study.

Adela Brahimaj1, Symen Ligthart1, M Arfan Ikram1,2,3, Albert Hofman1,4, Oscar H Franco1, Eric J G Sijbrands5, Maryam Kavousi1, Abbas Dehghan6.   

Abstract

OBJECTIVE: We aimed to investigate the role of serum levels of various apolipoproteins on the risk for type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: We used data from 971 individuals from the prospective population-based Rotterdam Study. We studied the association of HDL cholesterol (HDL-C), apoA1, apoCIII, apoD, and apoE as well as the ratios of apolipoproteins with apoA1 with the risk of T2D. All apolipoproteins, ratios, and HDL-C levels were naturally log-transformed to reach normal distribution. First, their cross-sectional associations with fasting glucose and insulin were investigated by using linear regression. Second, Cox proportional hazard models were used to examine whether apolipoproteins predict the risk for T2D among individuals free of diabetes at baseline. We also studied the apolipoproteins jointly by calculating the apolipoproteinic score from the first step and then performing Cox regression with it.
RESULTS: During a median follow-up of 13.5 years, diabetes developed in 110 individuals. After adjustment for age, sex, BMI, parental history of diabetes, hypertension, alcohol use, smoking, prevalent cardiovascular disease, and serum lipid-reducing agents, HDL-C (per 1 SD naturally log-transformed hazard ratio 0.74 [95% CI 0.57, 0.97], apoCIII (1.65 [1.42, 1.91]), apoE (1.36 [1.18, 1.55]), apoCIII-to-apoA1 ratio (1.72 [1.51, 1.95]), apoE-to-apoA1 ratio (1.28 [1.13, 1.45]), and apolipoproteinic score (1.60 [1.39, 1.83]) remained significant. Only apoCIII (1.42 [1.03, 1.96]) and apoCIII-to-apoA1 ratio (1.56 [1.04, 2.36]) survived the adjustment for triglycerides in the last model.
CONCLUSIONS: Serum apoCIII levels as well as apoCIII-to-apoA1 ratio are associated with incident T2D. They are associated independent of known risk factors and stronger than HDL-C levels.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28031419     DOI: 10.2337/dc16-1295

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  13 in total

1.  The Rotterdam Study: 2018 update on objectives, design and main results.

Authors:  M Arfan Ikram; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Albert Hofman
Journal:  Eur J Epidemiol       Date:  2017-10-24       Impact factor: 8.082

2.  A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins.

Authors:  Valentin Blanchard; Damien Garçon; Catherine Jaunet; Kevin Chemello; Stéphanie Billon-Crossouard; Audrey Aguesse; Aya Garfa; Gilles Famchon; Amada Torres; Cédric Le May; Matthieu Pichelin; Edith Bigot-Corbel; Gilles Lambert; Bertrand Cariou; Samy Hadjadj; Michel Krempf; Kalyane Bach-Ngohou; Mikaël Croyal
Journal:  J Lipid Res       Date:  2020-05-13       Impact factor: 5.922

3.  Urinary Apolipoprotein C3 Is a Potential Biomarker for Alzheimer's Disease.

Authors:  Yumi Watanabe; Yoshitoshi Hirao; Kensaku Kasuga; Takayoshi Tokutake; Kaori Kitamura; Shumpei Niida; Takeshi Ikeuchi; Kazutoshi Nakamura; Tadashi Yamamoto
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2020-09-11

4.  Structure-function relationships of HDL in diabetes and coronary heart disease.

Authors:  Mathias Cardner; Mustafa Yalcinkaya; Sandra Goetze; Edlira Luca; Miroslav Balaz; Monika Hunjadi; Johannes Hartung; Andrej Shemet; Nicolle Kränkel; Silvija Radosavljevic; Michaela Keel; Alaa Othman; Gergely Karsai; Thorsten Hornemann; Manfred Claassen; Gerhard Liebisch; Erick Carreira; Andreas Ritsch; Ulf Landmesser; Jan Krützfeldt; Christian Wolfrum; Bernd Wollscheid; Niko Beerenwinkel; Lucia Rohrer; Arnold von Eckardstein
Journal:  JCI Insight       Date:  2020-01-16

5.  High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia.

Authors:  Manja Koch; Steven T DeKosky; Matthew Goodman; Jiehuan Sun; Jeremy D Furtado; Annette L Fitzpatrick; Rachel H Mackey; Tianxi Cai; Oscar L Lopez; Lewis H Kuller; Kenneth J Mukamal; Majken K Jensen
Journal:  J Lipid Res       Date:  2019-12-31       Impact factor: 5.922

6.  Objectives, design and main findings until 2020 from the Rotterdam Study.

Authors:  M Arfan Ikram; Guy Brusselle; Mohsen Ghanbari; André Goedegebure; M Kamran Ikram; Maryam Kavousi; Brenda C T Kieboom; Caroline C W Klaver; Robert J de Knegt; Annemarie I Luik; Tamar E C Nijsten; Robin P Peeters; Frank J A van Rooij; Bruno H Stricker; André G Uitterlinden; Meike W Vernooij; Trudy Voortman
Journal:  Eur J Epidemiol       Date:  2020-05-04       Impact factor: 8.082

Review 7.  Dyslipidemia in Pediatric Type 2 Diabetes Mellitus.

Authors:  Bhuvana Sunil; Ambika P Ashraf
Journal:  Curr Diab Rep       Date:  2020-09-09       Impact factor: 4.810

Review 8.  High Density Lipoproteins and Diabetes.

Authors:  Blake J Cochran; Kwok-Leung Ong; Bikash Manandhar; Kerry-Anne Rye
Journal:  Cells       Date:  2021-04-09       Impact factor: 6.600

9.  Association of apolipoprotein Cs with new-onset type 2 diabetes mellitus: findings from the Chinese multi-provincial cohort study.

Authors:  Jiangtao Li; Dong Zhao; Jing Liu; Miao Wang; Jiayi Sun; Jun Liu; Yan Li; Qiuju Deng; Yue Qi
Journal:  BMJ Open       Date:  2021-11-16       Impact factor: 2.692

10.  Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity.

Authors:  Ji A Seo; Min-Cheol Kang; Won-Mo Yang; Won Min Hwang; Sang Soo Kim; Soo Hyun Hong; Jee-In Heo; Achana Vijyakumar; Leandro Pereira de Moura; Aykut Uner; Hu Huang; Seung Hwan Lee; Inês S Lima; Kyong Soo Park; Min Seon Kim; Yossi Dagon; Thomas E Willnow; Vanita Aroda; Theodore P Ciaraldi; Robert R Henry; Young-Bum Kim
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.